China Post Securities released a research report on April 26 stating that Hualan Biotech (002007.SZ) was given a purchase rating. The main reasons for the rating include: 1) The growth rate of blood products slowed down during the same period last year; 2

Zhitong Finance · Apr 26 18:02

China Post Securities released a research report on April 26 stating that Hualan Biotech (002007.SZ) was given a purchase rating. The main reasons for the rating include: 1) The growth rate of blood products slowed down during the same period last year; 2) the first batch of influenza vaccines was issued in April. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

中邮证券4月26日发布研报称，给予华兰生物（002007.SZ）买入评级。评级理由主要包括：1）去年同期高基数下，血制品增速有所放缓；2）流感疫苗4月获得首批次批签发。（每日经济新闻）

China Post Securities released a research report on April 26 stating that Hualan Biotech (002007.SZ) was given a purchase rating. The main reasons for the rating include: 1) The growth rate of blood products slowed down during the same period last year; 2

Risk Disclaimer

Statement